AstraZeneca PLC Files Director Shareholding Report

TL;DR

AZN filed its 6-K for director shareholdings - routine update.

AI Summary

AstraZeneca PLC filed a Form 6-K on November 10, 2025, reporting its shareholdings for Directors and Persons Disclosing Managerial Responsibilities (PDMRs). This filing is a routine report for foreign issuers and does not contain specific financial transaction details within the provided text.

Why It Matters

This filing provides transparency into the holdings of key company personnel, which can be an indicator of insider confidence in the company's future performance.

Risk Assessment

Risk Level: low — The filing is a standard regulatory disclosure and does not contain information that suggests a change in the company's risk profile.

Key Players & Entities

• AstraZeneca PLC (company) — Filer of the report
• 001-11960 (company) — SEC File Number for AstraZeneca PLC
• 20251110 (date) — Filing date and period of report

FAQ

From the Filing

0001654954-25-012757.txt : 20251110 0001654954-25-012757.hdr.sgml : 20251110 20251110121517 ACCESSION NUMBER: 0001654954-25-012757 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251110 FILED AS OF DATE: 20251110 DATE AS OF CHANGE: 20251110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251465253 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a9097g.htm DIRECTOR/PDMR SHAREHOLDING a9097g FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of November 2025   Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________       AstraZeneca PLC   INDEX TO EXHIBITS   1. Director/PDMR Shareholding   10 November 2025   Transaction by Person Discharging Managerial Responsibilities    AstraZeneca PLC (the Company) announces that, on 7 November 2025, it was notified by Pascal Soriot, Executive Director and Chief Executive Officer, that, on 7 November 2025, Mr Soriot ceased to be beneficially interested in 136,537 ordinary shares of $0.25 each in the Company, following the gift of those shares to family members for nil consideration.     Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).   1   Details of the person discharging managerial responsibilities / person closely associated a)   Name Pascal Soriot 2   Reason for the notification   a)   Position/status   Chief Executive Officer b)   Initial notification /Amendment Initial notification 3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a)   Name AstraZeneca PLC b)   LEI PY6ZZQWO2IZFZC3IOL08 4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a)   Description of the financial instrument, type of instrument   Identification code Ordinary Shares of US$0.25 each in AstraZeneca